Live Attenuated Influenza vaccine 2026/2027
Estimated value
£225.4m
Awarded value
£225.4m
Awarded 31 May 2026
Suppliers
1
Lots
1
1 awarded
Published
19 Jun 2026
Deadline 01 Jul 2026
Other contracts from UK Health Security Agency· 0
Most recent notices published by the same contracting authority.
No related contracts found.
Other contracts awarded to ASTRAZENECA UK LIMITED· 10
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| Live Attenuated Influenza Vaccine 2026/2027 | contract | — | 19 Jun 2026 |
| NHS National Branded Interim - 1 June 2026 | contract | — | 22 May 2026 |
| NHS National Branded Interim - 1 June 2026 | contract | — | 16 Apr 2026 |
| Generic, Branded Generic & Proprietary Medicinal Products - Group 16 | contract | — | 21 Aug 2025 |
| NHS National Framework for Transition products (Nilotinib and Ticagrelor) | contract | — | 20 Aug 2025 |
| NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National | contract | £9.4m | 24 Jul 2025 |
| NHS Framework Agreement for Branded Medicines – Tranche A London and South of England and Adult Influenza (National) - 01 September 2025 | contract | — | 24 Jul 2025 |
| NHS National Framework for Transition products (Nilotinib and Ticagrelor) | contract | — | 11 Jul 2025 |
| NHS National Framework for Transition products (Nilotinib and Ticagrelor) | contract | — | 11 Jul 2025 |
| NHS Branded Medicines Tranche Framework for London and South of England | contract | £13.1m | 20 Aug 2024 |